Preferred Label : neisseria meningitidis, serogroup a;
MeSH definition : Strains of Neisseria meningitidis responsible for most outbreaks of meningococcal
disease in Western Europe and the United States in the first half of the 20th century.
They continue to be a major cause of disease in Asia and Africa, and especially localized
epidemics in Sub-Sahara Africa.;
MeSH synonym : meningococci, serogroup a; meningococcus, serogroup a;
MeSH annotation : infection: coord IM with MENINGITIS, MENINGOCOCCAL (IM) or, if not meningitis, MENINGOCOCCAL
INFECTIONS (IM);
UNII : txid65699;
Origin ID : D038381;
UMLS CUI : C1136211;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
Manual BTNT mappings - CISMeF
Record concept(s)
Semantic type(s)
Strains of Neisseria meningitidis responsible for most outbreaks of meningococcal
disease in Western Europe and the United States in the first half of the 20th century.
They continue to be a major cause of disease in Asia and Africa, and especially localized
epidemics in Sub-Sahara Africa.
http://www.has-sante.fr/portail/jcms/c_2041961/fr/nimenrix-vaccins-meningococciques-a-c-w135-et-y-conjugues
http://www.has-sante.fr/portail/jcms/c_2041961/fr/nimenrix
2015
false
France
French
tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine
tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine
guidelines for drug use
meningitis, meningococcal
antibiotic therapy
evaluation of the transparency committee
insurance, health, reimbursement
vaccination
injections, intramuscular
meningococcal infections
neisseria meningitidis, serogroup a
vaccines, conjugate
neisseria meningitidis, serogroup C
neisseria meningitidis, serogroup W-135
neisseria meningitidis, serogroup y
meningococcal vaccines
meningococcal vaccines
polysaccharides, bacterial
tetanus toxoid
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
risk factors
infant
immunization schedule
immunization, secondary
drug interactions
child
adult
adolescent
treatment outcome
clinical trials, phase iii as topic
adaptive immunity
---
http://www.cochrane.org/fr/CD001093
2012
United Kingdom
France
French
antibiotic therapy
meta-analysis
meningitis, meningococcal
meningococcal vaccines
treatment outcome
child
neisseria meningitidis, serogroup a
french abstract
---
http://www.has-sante.fr/portail/jcms/c_1352587/nimenrix
http://www.has-sante.fr/portail/upload/docs/evamed/CT-12514_NIMENRIX_Insc_AVIS2_CT12514.pdf
2012
false
France
French
tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine
tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine
antibiotic therapy
evaluation of the transparency committee
insurance, health, reimbursement
vaccination
injections, intramuscular
meningococcal infections
neisseria meningitidis, serogroup a
vaccines, conjugate
neisseria meningitidis, serogroup C
neisseria meningitidis, serogroup W-135
neisseria meningitidis, serogroup y
meningococcal vaccines
meningococcal vaccines
polysaccharides, bacterial
tetanus toxoid
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
risk factors
infant
immunization schedule
immunization, secondary
drug interactions
child
adult
adolescent
treatment outcome
clinical trials, phase iii as topic
adaptive immunity
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61920725
2009
France
French
antibiotic therapy
polysaccharides, bacterial
meningococcal vaccines
vaccination
neisseria meningitidis, serogroup a
neisseria meningitidis, serogroup C
meningococcus A,C, bivalent purified polysaccharides antigen
adult
child
meningitis, meningococcal
meningococcal infections
injections, intramuscular
injections, subcutaneous
meningococcal vaccines
summary of product characteristics
package leaflet
---